In less than six years, Amneal Pharmaceuticals has become the seventh largest generic pharmaceutical manufacturer in the United States. The company has been recognized with awards, seen more than 118 million of its prescription drugs dispensed per year, built its infrastructure to a 35 billion-unit annual capacity and has nearly 240 Abbreviated New Drug Applications filed or in development. Despite its phenomenal growth, this award-winning company remains passionate about continued expansion across its current business segments as well as into new products, dosage forms and markets, all while maintaining its total commitment to quality and superior customer value and relationships.
At A Glance
Specialized Products and Packaging
Unit-Dose Packaged Oral Solids
Injectables (syringes, vials, bags)
The Amneal Institutional Value
Proactive, fully immersed into segment
Amneal recently extended its philosophy further into the institutional market with the creation of Amneal Institutional (AI)—a business unit dedicated to generic products and packaging designed to meet the specific needs of health systems, clinics and physician offices. With an average of more than 25 years in the pharmaceutical industry, AI’s account management team has extensive experience serving the institutional market, widely defined as hospitals and other acute care facilities, outpatient surgical and radiology services, oncology centers, home infusion service providers, long-term care centers, correctional facilities, specialty pharmacies and group purchasing organizations.
With a distinct product selection that includes specialty injectables (prefilled syringes, single-dose vials, pharmacy bulk packaging and premix bags) and unit-dose packaging, Amneal is now well positioned to fill the unique needs of these markets. Some of the near-term launches—products from a partnership with Agila Specialties—are on the FDA Drug Shortage List and should help address current market supply issues. Several other product launches are planned through year-end as well as a robust pipeline for 2014 and beyond. The new dosage forms join the same proven bulk oral solids, topicals and large-quantity oral liquid medications on which Amneal’s reputation was built, offering institutional pharmacies a broader selection of superb-quality generics.
Understanding the strategic direction of the industry, Amneal began moving into biologics in 2009 and expanded into biosimilars with the early 2012 acquisition of Therapeutic Proteins International (TPI), a biosimilars development firm in Chicago. TPI’s management team offers extensive, industry-wide experience in this rapidly evolving area of pharmaceuticals, in both the domestic and international markets. The company’s revolutionary patented disposable bioreactor-based manufacturing technology radically alters biologic production paradigms, enabling accelerated time to market. With 40-plus tests—five of which are patented—per product, TPI delivers the same superior quality and extraordinary consistency for which Amneal goods are known. Amneal anticipates the first FDA approval of its TPI biosimilar product in 2014.
Beyond stellar products, Amneal offers a unique collaborative business style to the institutional area. A dedicated and committed account management team boasts extensive experience from a variety of injectable manufacturers. This highly focused sales leadership group—together with Amneal’s transparent and responsive way of doing business—promises to deliver industry-recognized customer focus bolstered by unrelenting quality, development of non-price value and a consistent supply of essential products to meet the institutional pharmacy’s needs and help improve the health of its patients.
This corporate profile was reviewed and approved by Amneal Institutional.